Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 3, 2017
Reporting Period: Specific event date of August 3, 2017.
The filing reports the entry into a material definitive agreement and the creation of a direct financial obligation involving the amendment of existing promissory notes and the issuance of new warrants.
Key Financial Metrics and Obligations
- Debt Principal: $5,372,743 (aggregate outstanding principal balance of Promissory Notes as of August 3, 2017).
- Interest Rate: 10.00% per annum (accruing since January 2, 2017 due to defaults).
- Debt Maturity: Extended to December 31, 2018.
- Equity Issuance: 2,000,000 Class K Warrants issued unregistered.
- Warrant Terms: Exercise price of $0.11 per share; 10-year expiration; vested upon issuance.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Material Changes and Defaults
The Company has entered into a Third Amendment to two promissory notes originally dated August 1, 2005, with HealthTronics, Inc. Key changes include:
- Extension of Due Date: The maturity date was extended to December 31, 2018.
- Prepayment Provisions: Mandatory prepayment provisions were revised.
- Default Status: Events of default occurred and are continuing due to the Borrower's failure to make required interest payments on December 31, 2016, March 31, 2017, and June 30, 2017.
- Waiver Status: The Third Amendment did not waive the existing defaults.
Outlook, Risks, and Contingencies
Management Commentary: The filing states that the agreements are provided to disclose terms and do not constitute factual information about the Company's actual state of facts or conditions. Representations and warranties are for the benefit of the contracting parties only.
Risks and Contingencies:
- Continuing Default: The Company remains in default on interest payments, with interest accruing at a penalty rate of 10.00% per annum.
- Dilution: The issuance of 2,000,000 warrants at $0.11 per share introduces potential dilution to existing shareholders, subject to anti-dilution protections.
- Liquidity: The extension of debt suggests ongoing liquidity challenges, as the Company was unable to meet prior payment obligations.
Investor Verification Checklist
- Verify the total accrued interest on the $5,372,743 principal balance since January 2, 2017, given the 10.00% penalty rate.
- Confirm the specific terms of the "anti-dilution protection" attached to the Class K Warrants.
- Review the full text of the Third Amendment (Exhibit 10.1) to understand the revised mandatory prepayment provisions.
- Assess the Company's current cash position and ability to service the debt by the new December 31, 2018 maturity date.
- Check for any subsequent filings regarding the status of the defaults or additional interest payments.